OmniAb, Inc. (NASDAQ:OABI) Insider Charles S. Berkman Sells 8,215 Shares

OmniAb, Inc. (NASDAQ:OABI) insider Charles S. Berkman sold 8,215 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $3.68, for a total value of $30,231.20. Following the completion of the sale, the insider now directly owns 364,131 shares of the company’s stock, valued at approximately $1,340,002.08. This represents a 2.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

OmniAb Stock Performance

Shares of NASDAQ OABI opened at $3.67 on Thursday. The business has a 50 day simple moving average of $3.49 and a 200 day simple moving average of $3.91. OmniAb, Inc. has a 52 week low of $3.10 and a 52 week high of $6.55. The stock has a market cap of $518.28 million, a price-to-earnings ratio of -5.92 and a beta of -0.12.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Benchmark restated a “buy” rating and set a $8.00 price target on shares of OmniAb in a report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of OmniAb in a research note on Thursday, November 14th.

Institutional Trading of OmniAb

A number of institutional investors have recently added to or reduced their stakes in the business. Hsbc Holdings PLC acquired a new position in shares of OmniAb during the 4th quarter worth $38,000. Choreo LLC bought a new position in OmniAb during the fourth quarter valued at about $41,000. Rangeley Capital LLC acquired a new position in shares of OmniAb during the 4th quarter valued at about $41,000. KLP Kapitalforvaltning AS bought a new position in shares of OmniAb in the 4th quarter valued at approximately $49,000. Finally, CWC Advisors LLC. acquired a new stake in OmniAb in the 3rd quarter worth approximately $54,000. 72.08% of the stock is currently owned by institutional investors and hedge funds.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.